Sign in
4

Changes in Ownership

Tyra Biosciences, Inc. Filed Acc 0001209191-23-021947

Chief Executive Officer sold 4,327 shares at an average $16.07 ($69,556)

  • Chief Executive Officer acquired 4,327 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Harris Todd Chief Executive Officer 2023-03-29 Option exercise +1,420 $2.25 $3,195 1,702,696 D: show line 1 in the form
Harris Todd Chief Executive Officer 2023-03-29 Sale −1,420 $16.18 $22,981 1,701,276 D: show line 2 in the form
Harris Todd Chief Executive Officer 2023-03-30 Option exercise +2,407 $2.25 $5,416 1,703,683 D: show line 3 in the form
Harris Todd Chief Executive Officer 2023-03-30 Sale −2,407 $16.02 $38,552 1,701,276 D: show line 4 in the form
Harris Todd Chief Executive Officer 2023-03-31 Option exercise +500 $2.25 $1,125 1,701,776 D: show line 5 in the form
Harris Todd Chief Executive Officer 2023-03-31 Sale −500 $16.05 $8,023 1,701,276 D: show line 6 in the form
Open-market sales · 4,327 sh · avg $16.07 · $69,556

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Harris Todd Chief Executive Officer 2023-03-29 Option exercise · Stock Option (Right to Buy) −1,420 402,444 D: show line 7 in the form
Harris Todd Chief Executive Officer 2023-03-30 Option exercise · Stock Option (Right to Buy) −2,407 400,037 D: show line 8 in the form
Harris Todd Chief Executive Officer 2023-03-31 Option exercise · Stock Option (Right to Buy) −500 399,537 D: show line 9 in the form
Loading xslF345X04/doc4.xml…